Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0171 versus placebo for RSV respiratory tract infection after hematopoietic stem cell transplantation
2017-003356-23Phase 2Terminated
- Sponsor
- Ablynx
- Start
- Dec 2017
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing ALX-0171 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Time-weighted average change from baseline to day 7 in log RSV nasal viral load. Started Dec 2017; status: terminated.
02
Drugs
gontivimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2017-003356-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003356-23.